Another GLP-1 weight loss pill gets FDA approval, and it has fewer restrictions on how it’s used | CNN

The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. The orforglipron pill, called Foundayo, is made by Eli Lilly, which also sells the GLP-1 drugs Zepbound for obesity and Mounjaro for diabetes. Those are given as weekly injections and, along with rival drugs Wegovy and Ozempic, have transformed weight-loss and diabetes treatment, with millions of people taking the medicines. Foundayo is coming to market just months after the FDA approved the pill form of Novo Nordisk’s injectable obesity drug Wegovy. Both pills offer a new way to take GLP-1 medicines, so named for the hormone they mimic that’s important for appetite, digestion and insulin regulation. But Lilly says Foundayo represents an advance because, unlike the Wegovy pill, it can be taken at any time of day and without restrictions on food and water. “We’ve really designed this to fit into people’s lives as easily as possible,” Dr. Dan Skovronsky, Lilly’s chief scientific and product officer, told CNN. Weight-loss treatment is on the verge of a dramatic shift – again The Wegovy pill must be tak